Table 2 Ongoing clinical trials of combination treatment with EMT-modulating agents
From: Tumor cell plasticity in targeted therapy-induced resistance: mechanisms and new strategies
Clinical trial (NCT identifier) | Conditions | Treatments | Patients | n | Phase | States |
|---|---|---|---|---|---|---|
NCT02922777 | NSCLC | Bemcentinib + Docetaxel | Previously treated patients with advanced NSCLC | 23 | I | Active, not recruiting |
NCT02488408 | AML | Bemcentinib + Cytarabine + Decitabine | Patients with AML | 121 | I/II | Active, not recruiting |
NCT03184571 | NSCLC | Bemcentinib + Pembrolizumab | Previously treated patients with advanced NSCLC | 106 | II | Recruiting |
NCT02872259 | Melanoma | Bemcentinib + Dabrafenib + Trametinib | Patients with advanced stage IIIc / IV) melanoma | 92 | I/II | Recruiting |
NCT04364620 | NSCLC | AB-16B5 + Docetaxel | Previously treated patients with metastatic NSCLC | 40 | II | Recruiting |
NCT02452008 | Prostate Cancer | Galunisertib + Enzalutamide | Patients with metastatic castration-resistant prostate cancer | 60 | II | Recruiting |
NCT02672475 | Breast cancer | Galunisertib + Paclitaxel | Patients with metastatic androgen receptor negative or triple negative breast cancer | 29 | I | Active, not recruiting |
NCT01682187 | Nasopharyngeal carcinoma | Galunisertib + Gemcitabine + Cisplantin + PD-1 blocking antibody + Radiation | Patients with high-risk locoregionally advanced nasopharyngeal carcinoma | 206 | II | Not yet recruiting |
NCT03206177 | Ovarian / Uterine carcinosarcoma | Galunisertib + Paclitaxel/Carboplatin | Patients with newly diagnosed, persistent or recurrent carcinosarcoma of the uterus or ovary | 26 | I | Active, not recruiting |
NCT02688712 | Rectal adenocarcinoma | Galunisertib + Capecitabine + Fluorouracil + Surgery + Radiation | Patients with locally advanced rectal adenocarcinoma | 50 | II | Active, not recruiting |
NCT01582269 | Glioblastoma | Galunisertib + Lomustine | Patients with glioblastoma | 180 | II | Active, not recruiting |
NCT04396886 | Nasopharyngeal carcinoma | Bintrafusp alfa (α-PDL1/TGF-βRII fusion protein) | Previously treated patients with recurrent and metastatic non-keratinizing nasopharyngeal carcinoma | 37 | II | Recruiting |
NCT05005429 | Mesothelioma; lung | Bintrafusp alfa (α-PDL1/TGF-βRII fusion protein) | Previously treated advanced malignant pleural mesothelioma | 47 | II | Recruiting |
NCT04349280 | Urothelial cancer | Bintrafusp alfa (α-PDL1/TGF-βRII fusion protein) | Metastatic or locally advanced urothelial cancer | 25 | I | Active, not recruiting |
NCT04727541 | Biliary tract cancer; Cholangiocarcinoma | Bintrafusp alfa (α-PDL1/TGF-βRII fusion protein) | Patients with resectable biliary tract cancer | 24 | II | Recruiting |
NCT04396535 | NSCLC | Bintrafusp alfa (α-PDL1/TGF-βRII fusion protein) | Patients with advanced NSCLC | 80 | II | Active, not recruiting |
NCT05145569 | Ovarian cancer | Bintrafusp alfa (α-PDL1/TGF-βRII fusion protein) | Patients with metastatic advanced stage ovarian cancer | 33 | I | Not yet recruiting |
NCT04489940 | Breast cancer | Bintrafusp alfa (α-PDL1/TGF-βRII fusion protein) | Patients with HMGA2 expressing triple negative breast cancer | 11 | II | Active, not recruiting |
NCT02521844 | Solid tumors | ETC-1922159 + Pembrolizumab | Patients with advanced solid tumors | 89 | I | Recruiting |
